DexCom, Inc. DXCM
Set alert
As of Nov 2, 11:18 AM ET
- YTD
- +26.61%
- 1 year
- +44.33%
- Open
- 82.82
- Prev close
- 82.29
- Mkt cap
- 31.32B
- Vol
- 819.28K
- Avg vol
- 4.51M
- EPS
- 2.54
- P/E
- 33.06
- Div yield
- 0.00%
More statistics
- Low
- 82.58
- High
- 84.70
- Forward P/E
- 26.27
- Beta
- 1.48
- Short ratio
- 3.91
- Inst. own
- 106.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2027
- 50-d avg
- 85.98
- 200-d avg
- 74.50
- 1y target
- 96.19
5D chart
Events in this range
- Oct 29, 2026Earnings: 0.73; estimate 0.675; surprise 8.15%
- Oct 30, 2026Rating: StoneX · Buy → Buy
- Oct 30, 2026Rating: Barclays · Overweight → Overweight
Signals (137)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:55 AM | 23 minutes ago |
| MACD: Sell Signal | Nov 2, 10:55 AM | 23 minutes ago |
| SMA: Bullish | Nov 2, 10:35 AM | 43 minutes ago |
| SMA: Bearish | Nov 2, 10:30 AM | 48 minutes ago |
| RSI: Overbought | Nov 2, 10:20 AM | 58 minutes ago |
| SMA: Bullish | Nov 2, 10:15 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 10:10 AM | 1 hour ago |
| RSI: Overbought | Nov 2, 9:45 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 4:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
News
3 hours ago businesswire.com
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes…
-
2 days ago benzinga.com
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.
-
2 days ago benzinga.com
JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85
JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $82 to $85.
3 days ago zacks.com
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
-
3 days ago benzinga.com
Barclays Maintains Overweight on DexCom, Raises Price Target to $120
Barclays analyst Christopher Pasquale maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $115 to $120.
-
3 days ago benzinga.com
StoneX Maintains Buy on DexCom, Raises Price Target to $93
StoneX analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $93.
3 days ago seekingalpha.com
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
What DexCom (DXCM) Said on Its Q3 Earnings Call
DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing…
3 days ago zacks.com
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
3 days ago benzinga.com
DexCom Q3 2026 Earnings Call Transcript
DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
3 days ago benzinga.com
DexCom Q3 2026 Earnings Call Transcript
DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
3 days ago fool.com
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
These aren't top AI stocks, but the technology is helping improve their businesses.
3 days ago investors.com
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.
-
3 days ago benzinga.com
DexCom Raises FY2026 Sales Guidance from $5.180B-$5.250B to $5.200B-$5.250B vs $5.229B Est
DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.180 billion-$5.250 billion to $5.200 billion-$5.250 billion vs $5.229 billion estimate.
3 days ago businesswire.com
Dexcom Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
-
5 days ago benzinga.com
DexCom Announces Availability Of Dexcom G7 15 Day Continuous Glucose Monitoring System In Canada From November
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next…
5 days ago businesswire.com
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM)…
5 days ago benzinga.com
Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 13.07% on an annualized basis producing an average annual return of 26.01%. Currently, DexCom has a market capitalization of…
5 days ago prnewswire.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
6 days ago zacks.com
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
1 week ago gurufocus.com
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors
On October 21, 2026, DexCom Inc (DXCM) shares fell 6.4% to a current price of $80.26. This decline comes amidst a 52-week range of $54.11 to $92.59, highlightin
1 week ago benzinga.com
SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
1 week ago zacks.com
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
1 week ago defenseworld.net
DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Company Stock
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of…
2 weeks ago seekingalpha.com
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut…
2 weeks ago reuters.com
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J…
2 weeks ago reuters.com
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
-
2 weeks ago benzinga.com
DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65
Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology,…
2 weeks ago businesswire.com
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been…
-
3 weeks ago benzinga.com
BTIG Maintains Buy on DexCom, Raises Price Target to $96
BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $96.
-
3 weeks ago benzinga.com
Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115
Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweight rating and announces Price Target of $115.
3 weeks ago benzinga.com
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
-
1 month ago benzinga.com
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105
RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $105.
1 month ago benzinga.com
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and…
-
1 month ago benzinga.com
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on DexCom, Raises Price Target to $102
Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.
2 months ago benzinga.com
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
-
3 months ago benzinga.com
Argus Research Maintains Buy on DexCom, Raises Price Target to $96
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.
-
3 months ago benzinga.com
Citigroup Maintains Buy on DexCom, Raises Price Target to $88
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $84 to $88.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90
RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $85 to $90.
-
3 months ago benzinga.com
Mizuho Maintains Outperform on DexCom, Raises Price Target to $95
Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $90 to $95.
3 months ago benzinga.com
Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion
Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.
-
3 months ago benzinga.com
JP Morgan Maintains Neutral on DexCom, Raises Price Target to $82
JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $65 to $82.
-
3 months ago benzinga.com
Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95
Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90
Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $85 to $90.
3 months ago benzinga.com
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.
-
3 months ago benzinga.com
Stifel Maintains Buy on DexCom, Raises Price Target to $95
Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $95.
-
3 months ago benzinga.com
Benchmark Maintains Buy on DexCom, Raises Price Target to $82
Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $77 to $82.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on DexCom, Raises Price Target to $93
Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $87 to $93.